AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
bioAffinity Technologies, Inc. (NASDAQ:BIAF)
0.9448 USD
-0.425 31.037%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.37 |
|---|---|
| Change | -0.425 31.037% |
| 52 W H/L (in USD) | 15.894/0.693 |
| EBITDA (in USD) | -10.068M |
| PE Ratio | -- |
| Volume | 3172189 |
| Diluted Eps TTM | -8.66 |
| Total Assets (in USD) | 10.961M |
|---|---|
| Total Liabilities (in USD) | 3.683M |
| Revenue TTM (in USD) | 6.162M |
| Cash (in USD) | 6.45M |
| Market Cap (in USD) | 11.742 M |
| Revenue Per Share TTM | 3.580 |
| Gross Profit TTM (in USD) | 1.935M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
3300 Nacogdoches Road, San Antonio, TX, United States, 78217
210 698 5334
Employees: 57
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Ms. Maria Zannes J.D. | Founder, Pres, CEO & Director | 1956 |
| 2. | Dr. Vivienne I. Rebel M.D., Ph.D. | Exec. VP and Chief Medical & Science Officer | 1965 |
| 3. | Mr. Michael Edwards CPA, M.B.A. | Chief Financial Officer | 1967 |
| 4. | Mr. Xavier T. Reveles M.S. | VP of Operations | NA |
| 5. | Mr. Timothy P. Zannes J.D. | Exec. VP, Sec. & Gen. Counsel | 1953 |
| 6. | Dr. William Bauta Ph.D. | Sr. VP of Therapeutics | NA |
| 7. | Mr. Steven Girgenti | Founder & Executive Chairman of the Board | 1946 |
| 8. | Ms. Maria Zannes J.D. | Founder, President, CEO & Director | 1956 |
| 9. | Mr. Michael Dougherty C.P.A., M.B.A. | VP & CFO | 1979 |
| 10. | Mr. Xavier T. Reveles M.S. | Chief Operating Officer | 1970 |
Peers
Sector: Healthcare
Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
TMO
Thermo Fisher Scientific Inc |
-1.090 0.230% | 474 | 34.710 | 23.866 | 4.622 | 4.428 | 5.293 | 20.886 |
|
DHR
Danaher Corporation |
+0.250 0.138% | 181.46 | 29.090 | 28.011 | 5.669 | 3.198 | 5.999 | 19.094 |
|
A
Agilent Technologies Inc |
-2.220 1.700% | 130.98 | 34.360 | 26.385 | 6.587 | 7.136 | 6.781 | 23.557 |
|
IDXX
IDEXX Laboratories Inc |
+3.000 0.526% | 573.28 | 49.990 | 45.662 | 11.293 | 27.850 | 11.461 | 34.457 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -14.866M | -9.028M | -7.916M | -8.152M | -6.324M |
| Minority Interest | - | - | - | - | - |
| Net Income | -14.91M | -9.04M | -7.937M | -8.154M | -6.326M |
| Selling General Administrative | 9.914M | 9.943M | 6.791M | 2.727M | 0.881M |
| Gross Profit | 1.43M | 3.379M | 0.542M | 0.004M | -0.005M |
| Reconciled Depreciation | 0.505M | 0.606M | 0.108M | 0.01M | 0.005M |
| Ebit | -10.573M | -8.936M | -7.973M | -4.011M | -2.207M |
| Ebitda | -10.068M | -8.33M | -7.724M | -5.821M | -1.477M |
| Depreciation And Amortization | 0.505M | 0.606M | 0.25M | -1.81M | 0.73M |
| Operating Income | -10.573M | -8.953M | -7.973M | -4.011M | -2.207M |
| Other Operating Expenses | 16.734M | 18.315M | 10.506M | 4.016M | 2.207M |
| Interest Expense | 0.044M | 0.092M | 0.037M | 2.533M | 1.002M |
| Tax Provision | 0.044M | 0.012M | 0.019M | 0.002M | 0.002M |
| Interest Income | 0.023M | 0.018M | 0.148M | 0.047M | 0M |
| Net Interest Income | -0.021M | -0.075M | 0.047M | -2.486M | -1.001M |
| Income Tax Expense | 0.044M | 0.012M | 0.021M | 0.002M | 0.002M |
| Total Revenue | 6.162M | 9.362M | 2.532M | 0.005M | 0.001M |
| Total Operating Expenses | 12.003M | 12.332M | 8.515M | 4.015M | 2.207M |
| Cost Of Revenue | 4.732M | 5.983M | 1.99M | 0M | 0.005M |
| Total Other Income Expense Net | -4.293M | -0.075M | 0.057M | -4.141M | -4.118M |
| Net Income From Continuing Ops | -14.91M | -9.04M | -7.238M | -8.154M | -6.326M |
| Net Income Applicable To Common Shares | - | - | - | - | -6.326M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 10.961M | 6.514M | 8.222M | 12.182M | 1.453M |
| Intangible Assets | 0.717M | 0.775M | 0.833M | - | - |
| Other Current Assets | 0.52M | 0.423M | 0.321M | 0.12M | 0.004M |
| Total Liab | 3.683M | 3.912M | 3.366M | 1.139M | 17.244M |
| Total Stockholder Equity | 7.278M | 2.602M | 4.855M | 11.043M | -15.791M |
| Other Current Liab | 1.718M | 1.399M | 1.15M | 0.542M | 1.605M |
| Common Stock | 0.031M | 0.107M | 0.066M | 0.059M | 0.019M |
| Capital Stock | 0.031M | 0.107M | 0.066M | 0.059M | 0.019M |
| Retained Earnings | -68.554M | -53.644M | -44.604M | -36.667M | -28.513M |
| Good Will | 1.404M | 1.404M | 1.404M | - | - |
| Other Assets | - | - | - | - | 0.01M |
| Cash | 6.45M | 1.105M | 2.822M | 11.414M | 1.361M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 2.906M | 3.105M | 2.248M | 1.139M | 13.04M |
| Current Deferred Revenue | 0.042M | 0.024M | 0.033M | - | - |
| Net Debt | -5.289M | 0.396M | -1.243M | -11.162M | 10.004M |
| Short Term Debt | 0.384M | 0.694M | 0.46M | 0.252M | 11.204M |
| Short Long Term Debt | 0.105M | 0.172M | - | 0.252M | 11.204M |
| Short Long Term Debt Total | 1.161M | 1.501M | 1.579M | 0.252M | 11.364M |
| Other Stockholder Equity | 75.8M | 56.14M | 49.394M | -12134.473M | 12.704M |
| Property Plant Equipment | - | - | - | - | 0.005M |
| Total Current Assets | 7.565M | 2.695M | 3.973M | 11.962M | 1.438M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 0.542M | 1.139M | 0.812M | 0.01M | 0.002M |
| Long Term Debt | 0.041M | 0.02M | - | - | 0.16M |
| Inventory | 0.054M | 0.028M | 0.018M | 0.006M | 0.072M |
| Accounts Payable | 0.762M | 0.987M | 0.605M | 0.345M | 0.23M |
| Accumulated Other Comprehensive Income | - | - | - | - | - |
| Non Currrent Assets Other | 0.013M | 0.02M | 0.016M | 0.006M | 0.01M |
| Non Current Assets Total | 3.396M | 3.819M | 4.249M | 0.22M | 0.015M |
| Capital Lease Obligations | 1.014M | 1.309M | 1.579M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | - | -0.079M | -2.443M | -0.22M | 0M |
| Total Cashflows From Investing Activities | -0.061M | -0.079M | - | - | - |
| Total Cash From Financing Activities | 14.734M | 5.628M | -0.345M | 14.344M | 3.327M |
| Net Income | -14.91M | -9.04M | -7.937M | -8.154M | -6.326M |
| Change In Cash | 5.344M | -1.716M | -8.592M | 10.053M | 1.278M |
| Begin Period Cash Flow | 1.105M | 2.822M | 11.414M | 1.361M | 0.083M |
| End Period Cash Flow | 6.45M | 1.105M | 2.822M | 11.414M | 1.361M |
| Total Cash From Operating Activities | -9.329M | -7.265M | -6.038M | -4.071M | -2.049M |
| Depreciation | 0.505M | 0.606M | 0.25M | 0.01M | 0.005M |
| Other Cashflows From Investing Activities | -0.061M | -0.079M | - | - | - |
| Dividends Paid | - | - | - | 0M | - |
| Change To Inventory | -0.026M | -0.009M | -0.013M | -0.006M | 0M |
| Sale Purchase Of Stock | - | - | - | -0M | - |
| Other Cashflows From Financing Activities | 14.734M | 1.446M | -0.345M | 9.012M | 6.834M |
| Capital Expenditures | 0.061M | 0.079M | 0.023M | 0.22M | 0M |
| Change In Working Capital | 0.594M | 0.18M | 0.901M | 0.114M | 0.633M |
| Other Non Cash Items | 4.482M | 0.99M | 0.964M | 3.71M | -0.244M |
| Free Cash Flow | -9.389M | -7.344M | -6.061M | -4.291M | -2.049M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 55543 |
| 2. | Abante Quant Value FI | 4 months ago | 43171 |
| 3. | Fidelity Extended Market Index | 3 months ago | 29770 |
| 4. | NT Ext Equity Mkt Idx Fd - L | 2 months ago | 12412 |
| 5. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 2 months ago | 4898 |
| 6. | Fidelity Series Total Market Index | 3 months ago | 4398 |
| 7. | Spartan Total Market Index Pool G | 3 months ago | 2965 |
| 8. | Fidelity Nasdaq Composite Index | 3 months ago | 601 |
| 9. | Fidelity Total Market Index | 3 months ago | 456 |
| 10. | NT Ext Equity Mkt Idx Fd - NL | 2 months ago | 313 |
| 11. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 months ago | 245 |
| 12. | Northern Trust Extended Eq Market Idx | 8 months ago | 142 |
| 13. | Spartan Extended Market Index Pool F | 3 months ago | 89 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Geode Capital Management, LLC | 5 months ago | 30422 |
| 2. | Citadel Advisors Llc | 5 months ago | 11631 |
| 3. | TWO SIGMA SECURITIES, LLC | 5 months ago | 11125 |
| 4. | Tower Research Capital LLC | 5 months ago | 3904 |
| 5. | Bank of America Corp | 8 months ago | 1684 |
| 6. | IFP Advisors, LLC | 5 months ago | 833 |
| 7. | UBS Group AG | 8 months ago | 143 |
| 8. | Citigroup Inc | 8 months ago | 75 |
| 9. | Morgan Stanley - Brokerage Accounts | 8 months ago | 3 |
| 10. | CapTrust Financial Advisors | 8 months ago | 0 |
| 11. | Creative Planning Inc | 8 months ago | 0 |
| 12. | State Street Corp | 8 months ago | 0 |
| 13. | Hanson Mcclain Inc | 5 months ago | 0 |
| 14. | Sabby Management LLC | 5 months ago | 0 |
| 15. | Northern Trust Corp | 8 months ago | 0 |
| 16. | FMR Inc | 5 months ago | 0 |
| 17. | Scientech Research LLC | 5 months ago | 0 |
| 18. | Larson Financial Group, LLC | 5 months ago | 0 |
| 19. | Vanguard Group Inc | 5 months ago | 0 |
| 20. | StoneX Group Inc | 8 months ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...